Torrent Pharmaceuticals Limited once again expands its recall for Losartan potassium tablets and Losartan potassium / hydrochlorothiazide tablets because they contain "N-methylnitrosobutyric acid (NMBA), a potential carcinogenic impurity, above the acceptable daily intake levels released by the FDA," according to
US Food and Drug Administration website.
The recall was extended to include 36 lots of Losartan potassium tablets and 68 lots of Losartan potassium / hydrochlorothiazide tablets. The tablets treat hypertension and hypertensive patients with left ventricular hypertrophy and nephropathy in patients with type 2 diabetic.
For a complete list of the tablets affected by the recall
click here.
Patients "should continue to take their medication as the risk of injury to the patient may be higher if treatment is stopped immediately without any other alternative treatment."
Consumers with medical issues regarding this recall or reporting of adverse events event can contact Torrent Pharmaceuticals Limited at: [1
FB.init ({
AppId: & # 39; 1575767939378722 & # 39 ;,
xfbml: true,
version: & # 39; v2.9 & # 39;
});
};
(function (d, s, id) {
var js, fjs = d.getElementsByTagName (s) [0];
if (d.getElementById (id)) {return;}
js = d.createElement (s); js.id = id;
js.src = "http://connect.facebook.net/en_US/sdk.js";
fjs.parentNode.insertBefore (js, fjs);
} (document, & # 39; script & # 39 ;, & # 39; facebook-jssdk & # 39;));
Source link
